Skip to main content
. Author manuscript; available in PMC: 2015 Jul 1.
Published in final edited form as: Bone Marrow Transplant. 2014 Sep 29;50(1):139–141. doi: 10.1038/bmt.2014.210

Table 1.

Patient & Treatment Characteristics and Outcomes (N=89)

VARIABLE All patients
(N=89)		 TKI Exposure
(n=55)		 TKI non-exposure
(n=34)
Patient gender (Female/Male) 36(40%) / 53(60%) 22 (40%) / 33 (60%) 14 (41%) / 20 (59%)
Age (years) at HCT: median (range) 44 (18 - 62) 45 (18 - 62) 41 (20 − 59)
Time (months) from diagnosis to HCT
median (range)		 8.4 (1.8 - 125.9) 5.5 (1.8 - 125.9) 18 (3 − 123.1)
Diagnosis
  ALL Ph+
  CML
48(54%)
41(46%)
36 (65%)
19 (35%)
12 (35%)
22 (65%)
Donor type
  Matched Sibling
  Mismatched Sibling
  Matched Unrelated Donor
  Mismatched Unrelated Donor
48(54%)
1 (1%)
12(14%)
28 (31%)
33 (60%)
0 (0%)
6 (11%)
16 (29%)
15 (44%)
1 (3%)
6 (18%)
12 (35%)
Conditioning regimen
  Reduced intensity
  Myeloablative
  Radiation-based
  Non-radiation-based
15(17%)
74(83%)
59 (66%)
30 (34%)
11 (20%)
44 (80%)
40 (73%)
15 (27%)
4 (12%)
30 (88%)
19 (56%)
15 (44%)
GVHD prophylaxis
  Sirolimus/Tacrolimus-based
  Tacrolimus/Methotrexate-based
  Cyclosporine/MMF
73 (82%)
14(16%)
2(2%)
46 (85%)
7 (11%)
2 (4%)
27 (79%)
7 (21%)
0 (0%)
Time (months) to TKI start:
median (range)		 1.9 ( 0.7-17.9) 1.9 ( 0.7-17.9) N/A
Duration (months) of TKI exposure*:
median (range)		 9.1 (0.1-89.4) 9.1 (0.1-89.4) N/A
Acute GVHD
  None
  Grade I
  Grade II
  Grade III
  Grade IV
36(40%)
11 (12%)
27 (30%)
12 (14%)
3 (4%)
24 (43%)
7 (13%)
16 (29%)
7 (13%)
1 (2%)
12 (35%)
4 (12%)
11 (32%)
5 (15%)
2 (6%)
Chronic GVHD
  None
  Limited
  Extensive
  Died Prior to Day +100
13(14%)
6 (7%)
64 (72%)
6(7%)
9 (16%)
5 (9%)
39 (71%)
2 (4%)
4 (12%)
1 (3%)
25 (73%)
4 (12%)
Sclerodermatous GVHD
  Time of Onset Median (months)		 15 (17%)
16.8 (6.7-53.7)		 8 (15%)
13.8 (10.3-33.1)		 7 (21%)
17.1 (6.7-53.7)
2-year Overall Survival 72.5% ( 95% CI 61.8-80.7) 73.8% (59.8 − 83.6) 70.4% (51.9 − 82.8)
2-year Progression-Free Survival 65.9% (95% CI 54.9- 74.8) 65.1% (50.9 − 76.2) 67.3% (48.7 − 80.4)
2-year Relapse/Progression
(cumulative incidence)		 14.8% (95% CI 8.9-24.3) 22.0% (13.3 − 36.2) 3.1% (0.4 − 21.1)

HCT, hematopoietic cell transplantation; TKI, tyrosine kinase inhibitor; GVHD, graft-versus-host disease; MMF, mycophenolate mofetil; scGVHD, sclerodermatous graft-versus-host disease

*

Duration of exposure defined as start of TKI until discontinuation, last follow-up, or development of scGVHD, whichever occurred first.